Table 3.
Annualized percentage change in BMD over 4 yr of follow-up for 1 sd increase in baseline pentosidine (log-transformed)
| Minimally adjusteda
|
Multivariable modelb
|
|||||
|---|---|---|---|---|---|---|
| Regression coefficient | 95% CI | P | Regression coefficient | 95% CI | P | |
| Total hip | −0.146 | (−0.243, −0.050) | 0.003 | −0.072 | (−0.161, 0.017) | 0.112 |
| Femoral neck | −0.185 | (−0.307, −0.062) | 0.003 | −0.125 | (−0.248, −0.002) | 0.047 |
| Trochanter | −0.218 | (−0.334, −0.101) | <0.001 | −0.156 | (−0.271, −0.041) | 0.008 |
a
Adjusted for age, race, and gender.
b
Adjusted for age, race, gender, current smoker, baseline BMD, baseline weight, weight change during 4-yr follow-up, cystatin- C, A1C, diabetes, and use of the following: insulin, metformin, sulfonylureas, thiazolidinediones, other oral hypoglycemic medications, vitamin D supplements, calcium supplements, oral steroids, osteoporosis drugs (bisphosphonates, calcitonin, raloxifene), thiazide diuretics, statins, and oral estrogen.